Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody
T. Arai (Sakai, Japan), T. Kasai (Sakai, Japan), A. Matsumuro (Sakai, Japan), C. Sugimoto (Sakai, Japan), M. Hirose (Sakai, Japan), N. Takeuchi (Sakai, Japan), K. Katayama (Sakai, Japan), M. Akira (Sakai, Japan), M. Kitaichi (Tanabe, Japan), Y. Inoue (Sakai, Japan)
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Disease area: Interstitial lung diseases
Abstract Introduction: Autoimmune pulmonary alveolar proteinosis (APAP) is caused by macrophage dysfunction due to anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody. APAP complicated with sarcoidosis is rarely reported. Subject and Methods: We have diagnosed two cases of APAP complicated with sarcoidosis. We have measured serum levels of anti-GM-CSF autoantibody in our institute, and investigated the changes of its serum levels during the clinical course. Results: Case 1 is 42-years old female and Case 2 is 51-years old male at the diagnosis of sarcoidosis. Serum anti-GM-CSF antibody was positive in both cases. Case 1 was a typical APAP diagnosed at the age of 29 with milky bronchoalveolar lavage and crazy paving pattern on high-resolution CT. APAP was resolved after GM-CSF inhalation therapy at the age of 30 and sarcoidosis with lung, skin and eye lesions, occurred after the 10-year stable period of APAP. Case 2 was diagnosed as APAP and sarcoidosis, simultaneously. Surgical lung biopsy specimens showed granulomatous lesion consistent with sarcoidosis and intra-alveolar Periodic Acid Schiff stain-positive proteinaceous material compatible with APAP. Sarcoidosis lesions were also observed in skin and eye. In both cases, serum levels of angiotensin converting enzyme was decreased and dyspnea with hypoxemia was improved after the corticosteroid therapy. In both cases, APAP lesions were limited and serum levels of anti-GM-CSF antibody was low at the diagnosis of sarcoidosis. Conclusions: Anti-GM-CSF autoantibody was associated with clinical couse. Financial support : This study was partially granted from AMED to Y. Inoue and T. Arai.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Arai (Sakai, Japan), T. Kasai (Sakai, Japan), A. Matsumuro (Sakai, Japan), C. Sugimoto (Sakai, Japan), M. Hirose (Sakai, Japan), N. Takeuchi (Sakai, Japan), K. Katayama (Sakai, Japan), M. Akira (Sakai, Japan), M. Kitaichi (Tanabe, Japan), Y. Inoue (Sakai, Japan). Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody. 3016
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012
Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010
Cross-sectional and longitudinal measurement of autoantibody levels against GM-CSF is useful for predicting clinical courses of in autoimmune pulmonary alveolar proteinosis. Source: International Congress 2017 – Rare diseases Year: 2017
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
Clinical and paraclinical manifestations of pulmonary alveolar proteinosis in children Source: Eur Respir J 2007; 30: Suppl. 51, 402s Year: 2007
Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002
Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016
Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphysema Source: Eur Respir J 2009; 33: 219-221 Year: 2009
Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009
Lymphocytes populations in bloods and lungs in patients with auto-immune pulmonary alveolar proteinosis Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011
Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013
Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016
Occupational and environmental impact on the clinical course of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012